Drug Profile
BR 4628
Alternative Names: BR-4628Latest Information Update: 31 Aug 2015
Price :
$50
*
At a glance
- Originator Bayer HealthCare Pharmaceuticals
- Class Dihydropyridines; Heart failure therapies
- Mechanism of Action Mineralocorticoid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Heart failure
Most Recent Events
- 30 Nov 2012 Phase-II clinical trials in Heart failure in Germany (unspecified route)
- 01 Mar 2011 Bayer Schering Pharma is now called Bayer Healthcare Pharmaceuticals
- 28 Sep 2007 Preclinical trials in Congestive heart failure in Germany (unspecified route)